From lab bench to market: six women founders from the EIC Women Leadership Programme

Turning scientific discovery into a business that reaches patients, industry or cities requires more than a prototype. It requires leadership, regulatory navigation, manufacturing scale and commercial traction. The European Innovation Council Women Leadership Programme aims to strengthen those leadership and strategic capabilities for women researchers and founders. This article profiles six entrepreneurs from across Europe whose companies illustrate how deep scientific research is being packaged into ventures targeting therapeutic gaps, sustainable food production, trustworthy AI, industrial IoT efficiency and point of care diagnostics.

What the profiles show at a glance

The six companies operate in different domains and at different maturity stages. Some are supported by the EIC Accelerator or Transition streams. Others were recognised through Women TechEU or the EIT. Common threads include an origin in academic research, a deep-tech technical core, and claims of easier adoption because the product integrates with existing clinical or industrial workflows. Those claims are plausible but require independent validation through clinical trials, pilots and third-party evaluations before wide adoption.

Profiles

SINDREL MedTech — Audrey Franceschi Biagioni, Co-founder and CEO, Trieste, Italy

Problem and market. Epilepsy affects more than 50 million people globally. Around a third remain refractory to current drug regimens. Many therapies rely on continuous systemic dosing which can produce side effects and poorly controlled episodes.

Technology. SINDREL has developed a graphene-based, electrically controlled implantable drug delivery platform that releases medication on demand at the target site. The concept is to reduce systemic exposure while improving efficacy through precise local dosing. The company was initially focused on epilepsy but the platform could be applied to other chronic diseases requiring personalised dosing.

Founder background. Audrey Franceschi Biagioni has a research track record in neuroscience, drug delivery and nanomaterials. She moved the graphene device from laboratory development towards clinical translation and now leads strategy and business development.

Support and stage. SINDREL has received backing from EIC instruments including EIC Transition and EIC Accelerator support has been mentioned in company materials. The team faces typical translation challenges such as preclinical validation, regulatory classification and human safety testing, and the capital required for manufacturing scale.

MASAP — Ligia Iuga-Roman, Co-founder and CFO, Bucharest, Romania

Problem and market. Agriculture accounts for a large share of freshwater use globally. Climate change and urbanisation increase pressure on local food systems. Small and mid-sized producers need ways to produce food reliably, reduce water use and lower emissions.

Technology. MASAP builds modular containerised aquaponics systems. These combine fish rearing and hydroponic plant cultivation in a recirculating system. Automation manages feeding, water recirculation and environmental parameters while sensors monitor water quality and plant performance. The container becomes an engine that can connect to protected growing spaces like greenhouses.

Founder background. Ligia Iuga-Roman brings finance, operations and partnership development skills. She leads MASAP’s commercial and operational strategy as the design moves from pilots to scalable deployments.

Support and stage. MASAP grew through EIT support and took part in regional green startup accelerators including ClimAccelerator and SCION. The firm emphasises modularity, automation and integrated renewable energy to reduce operational emissions and water footprint. Major questions for customers include total cost of ownership, technical reliability, and local market channels for both fish and crops.

Progressio.ai — Margaret Hartnett, Co-founder, London, United Kingdom

Problem and market. The EU AI Act and other governance frameworks will require organisations to show traceable evidence that AI systems were designed and tested responsibly. Evidence for compliance is often dispersed across engineering, testing, quality and supplier records and is difficult to reconcile at scale.

Technology. Progressio.ai automates evidence-based assessments. The platform extracts structured requirements from laws, standards, policies and contracts. It then maps artefacts to these requirements, evaluates provenance and evidential value, and reconciles contradictions. The output identifies what is supported, missing or uncertain with traceability to originating documents.

Founder background. Margaret Hartnett is an AI researcher turned patent attorney and technology adviser with more than 25 years of experience. She has led growth in AI ventures before co-founding Progressio.ai and brings expertise in IP, commercialisation and technical governance.

Support and stage. Progressio.ai is a Women TechEU recognised company. The product targets regulated sectors such as automotive, medtech and robotics where documentation and assurance requirements are demanding. Key challenges are integration with existing engineering toolchains, handling diverse data formats and proving the platform itself in audits or regulatory contexts.

bitteiler — Maroua Taghouti, Co-founder and CTO, Dresden, Germany

Problem and market. Industrial IoT deployments generate huge volumes of sensor data. Transmitting that data is limited by bandwidth, battery life and energy cost. Organisations must choose between reducing data fidelity or increasing operational cost.

Technology. bitteiler develops AI-powered on-device data compression for sensors. The approach performs intelligent compression at the edge so that sensors can transmit richer data with lower energy consumption and longer battery life. The company claims this enables scaling sensor networks without changing existing infrastructure.

Founder background. Maroua Taghouti holds a PhD in Communication Networks from TU Dresden. She moved academic research into a company and now leads productisation, embedded implementation and industrial validation.

Support and stage. bitteiler has been recognised by Women TechEU and won awards including a placement at GITEX Europe Supernova All-Stars. The business case depends on demonstrated compression performance across different sensor modalities, integration with device firmware and robustness in production environments.

Batea Oncology — Sonia Martínez Arca, Co-founder and CEO, Santiago de Compostela, Spain

Problem and market. Glioblastoma multiforme is an aggressive brain tumour with a five year survival rate below 5 percent. Recurrence after surgery is common because invasive cells remain at resection margins and are resistant to radiotherapy.

Technology. Batea Oncology developed GlioHook, a class III implantable medical device that aims to trap residual tumour cells at the surgical margin and increase their radiosensitivity. The concept is to focalise residual disease during the gap before radiotherapy, potentially reducing recurrence while integrating into existing clinical workflows without replacing standard care.

Founder background. Sonia Martínez Arca holds a PhD in Molecular and Cellular Biology and has over 15 years of experience in biotech, technology transfer and venture leadership. She leads partnerships and clinical translations for Batea.

Support and stage. Batea was recognised through Women TechEU and reported preclinical safety and survival benefits in animal models. The company aims to move into a Phase I clinical trial planned for 2025 according to company materials. Clinical translation of implantable oncology devices is capital and time intensive. Regulators and clinicians will require rigorous human safety and efficacy evidence before adoption.

CellFlow — Yonca Belce, Co-founder and Chief Scientific Officer, Barcelona, Spain

Problem and market. Blood cell separation is a routine pre-analytical step for diagnostics and regenerative medicine. Conventional centrifugation depends on lab infrastructure, risks cell damage and can be time consuming and costly. That reduces access to diagnostics and complicates point-of-care and decentralized workflows.

Technology. CellFlow has developed a single-use, portable lab-on-chip microfluidic platform that isolates target cells directly from whole blood in a single step without centrifugation. The closed system aims to preserve cell integrity, reduce contamination risk and simplify workflows for applications such as liquid biopsy, regenerative medicine and immune diagnostics.

Founder background. Yonca Belce has a PhD in Materials Science and leads the company’s scientific and product development. The team combines microfluidics, materials and biomedical expertise.

Support and stage. CellFlow was selected by Women TechEU and positions itself as a medtech innovator tackling sample preparation bottlenecks. Important validation steps include reproducibility across patient samples, regulatory pathways for single-use disposables and establishing distribution channels into hospitals and diagnostics labs.

Comparative snapshot

About the EIC Women Leadership Programme and broader EIC support

The EIC Women Leadership Programme launched as a pilot in 2021. It provides cohort-based training, personal mentoring and business coaching for women in research and entrepreneurship. The programme has delivered support to more than 300 women across nine cohorts. Participants have reported measurable gains in entrepreneurial skills and leadership confidence according to EIC materials.

The EIC Business Acceleration Services ecosystem offers a wide suite of supports including coaching, access to corporates and procurers, investor readiness and trade fair support. Complementary initiatives aimed at women include Women TechEU for early stage women-led deep tech startups and the European Prize for Women Innovators. The EIC has increased attention to gender balance with target and portfolio measures noted in public documents.

Analysis, caveats and what to watch next

These six companies represent a positive example of academic research moving towards commercialisation under European innovation programmes. The EIC and EIT supports reduce early financial risk and increase visibility. That said the road from lab to scalable product is long and often nonlinear. The medtech and biotech ventures face clinical trial timelines, stringent regulatory gatekeeping and manufacturing complexity. The hardware and industrial software firms will need to demonstrate repeatable performance in production settings and to integrate into customer operations. For AI governance products, the practical test is whether regulators, certification bodies and auditors accept automated evidence artefacts without extensive human mediation.

Investors and public procurers will look for objective milestones such as clinical trial results, validated pilots with paying customers, reproducible performance metrics and defensible intellectual property. Programmes like Women TechEU and the EIC Women Leadership Programme help founders prepare for those milestones by building leadership skills and networks. They do not, by themselves, remove the need for rigorous validation or for the capital required to scale manufacturing and international sales.

Practical implications for entrepreneurs and policymakers

Entrepreneurs should treat EU support as one element of a multisource financing and validation strategy. Use grants and acceleration services to de-risk key technical and regulatory questions. Build early partnerships with clinicians, industrial integrators and procurement bodies to shorten time to pilot. For policy makers, continued progress requires funding that covers not only R&D but also the expensive phases of clinical validation and manufacturing scale. Policymakers should also focus on standardised testbeds and procurement pathways that reduce fragmentation and encourage purchasers to adopt validated European technologies.

How to follow and apply

The EIC Community platform, EIC Business Acceleration Services and the EIC BAS newsletter are the official entry points for open calls including the next intake to the EIC Women Leadership Programme. Women founders, researchers and innovators can apply to public calls available on the EIC Community. For those seeking connections, the EIC Service Catalogue lists partner services that may be cofunded through programmes such as EIC ACCESS+.

If you have questions specifically about the EIC Women Leadership Programme, contact the EIC Community helpdesk and choose the 'EIC Women Leadership Programme' category. Keep an eye on open calls if you are considering applying to Women TechEU, EIC Transition or the EIC Accelerator.

Final note

Profiles like these are useful to highlight talent and possible pathways for research translation. They should not be read as independent validation of clinical or commercial outcomes. For investors, partners and procurers, the next step is to look for the hard evidence behind claims. For journalists and observers, these stories are worth following because they reveal how European funding, mentorship and networks are being used to create companies that could scale beyond the lab.